針對一項(xiàng)新型無創(chuàng)性宮頸癌檢測設(shè)備的臨床試驗(yàn)獲得了美國Emory大學(xué)(Atlanta, GA, USA)Gerogia研究聯(lián)盟及其合作伙伴SpectRx公司(Norcross, GA, USA)的資金支持，該公司是這種設(shè)備的開發(fā)者。

這項(xiàng)撥款將被用于Grady Memorial醫(yī)院(Atlanta, GA, USA)的該技術(shù)的臨床試驗(yàn)，將由Emory大學(xué)的Lisa Flowers醫(yī)生負(fù)責(zé)。這種無創(chuàng)宮頸癌檢測設(shè)備使用技術(shù)沒有痛苦無需侵入鑒別癌癥和癌前病變，通過分析宮頸的光放射來完成。這種設(shè)備建立宮頸圖像，突出顯示病變位置和嚴(yán)重程度。這項(xiàng)技術(shù)通過在細(xì)胞水平檢測生化與形態(tài)學(xué)改變來區(qū)分正常和病變組織。與Pap檢測不同，該技術(shù)需要組織樣本或者實(shí)驗(yàn)室分析，而且可以快速得到檢查結(jié)果。

一項(xiàng)臨床前的關(guān)鍵研究，由美國國立癌癥研究員資助，提示這種檢測把Pap假陽性檢測結(jié)果所導(dǎo)致的非必要的隨訪手術(shù)降低了55％，為節(jié)約了醫(yī)療保健系統(tǒng)的巨大支出。宮頸癌是最常見的位列第三位的女性癌癥。

Flowers醫(yī)生說：“這種新技術(shù)為解決目前存在的宮頸癌早期檢測的障礙提供了可能。它免除了患者在檢測之后數(shù)日內(nèi)焦急等待檢查結(jié)果，消除了許多假陽性檢測結(jié)果，這種假陽性無論對患者還是醫(yī)療保健系統(tǒng)都是一個(gè)沉重的負(fù)擔(dān)?！?
 
Trials for Cervical-Cancer Detection Device
 
Clinical trials for a new noninvasive cervical-cancer detection device are being supported by a grant to Emory University (Atlanta, GA, USA) from the Georgia Research Alliance (GRA) in partnership with SpectRx, Inc. (Norcross, GA, USA), the developer of the device.

The grant will be used for the clinical trial of the technology at Grady Memorial Hospital (Atlanta, GA, USA) under the guidance of Dr. Lisa Flowers of Emory University. The noninvasive cervical-cancer detection device uses proprietary technology to identify cancers and precancers painlessly and noninvasively by analyzing light reflected from the cervix. The device creates an image of the cervix that highlights the location and severity of disease. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphologic changes at the cellular level. Unlike Pap tests, this test does require a tissue sample or laboratory analysis, and results are instantly available.

A pre-pivotal clinical study, sponsored by the U.S. National Cancer Institute, indicated that the test could reduce by 55% the number of unnecessary follow-up procedures as a result of false-positive Pap results, with huge cost savings to the healthcare system. Cervical cancer is the third most common cancer among women.

“This new technology offers the potential to overcome many of the barriers to early detection of cervical cancer that exist today,” said Dr. Flowers. “It could eliminate the anxiety of waiting for days for test results and many of the false-positive results that are a burden on the patient and the healthcare system.”